A once-daily (o.d.) formulation of alfuzosin has recently been developed in order to improve the convenience of dosing and to provide optimal pharmacokinetic coverage over a 24-h period. The results of two double-blind, placebo-controlled phase III studies of similar design that included 983 patients with LUTS that suggested BPH have confirmed that alfuzosin 10mg o.d. is a 24-h effective treatment for both symptoms and flow rates, and that there is no additional benefit in using a higher dosage. In addition, alfuzosin is the only α1-blocker that has demonstrated a significant decrease in post-void residual urine, a known risk factor for acute urinary retention, as well as the incidence of acute urinary retention in comparison with a placebo. Administered without an initial dose titration, alfuzosin 10mg o.d. is well tolerated, with a low incidence of postural hypotension (<1%) and no significant changes in blood pressure compared with a placebo, even in elderly and hypertensive patients. Ejaculation disorders were rarely reported and did not show an evident causal relationship to treatment. Alfuzosin 10mg o.d. also exhibits an excellent sexual side-effect profile, with no deleterious impact on this important aspect of quality of life for BPH patients.